Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silk Road Medical, Inc (SILK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.15-1.68 (-3.75%)
At close: 04:00PM EDT
43.13 -0.02 (-0.03%)
After hours: 04:05PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close44.83
Open44.74
Bid43.31 x 1100
Ask45.42 x 900
Day's Range42.62 - 44.53
52 Week Range27.21 - 67.49
Volume221,551
Avg. Volume320,820
Market Cap1.521B
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SILK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silk Road Medical, Inc.
    Analyst Report: Silk Road Medical IncBased in Sunnyvale, California, Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that may cause strokes. The TCAR procedure involves threading a balloon catheter into the carotid artery from an incision near the groin to expand the narrowed artery. In parallel with the catheter procedure, another device is deployed to temporarily reverse blood flow to the brain in the treated artery in order to prevent any broken off clots from moving to the brain.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Silk Road Medical Reports Second Quarter 2022 Financial Results

    SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022. “We achieved several important milestones in the second quarter. We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 mi

  • GlobeNewswire

    Silk Road Medical to Report Second Quarter 2022 Financial Results on July 26, 2022

    SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2022 after market close on Tuesday, July 26, 2022. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Those interested in listening to the audio webcast should register online here. Partic

  • GlobeNewswire

    Silk Road Medical Announces Post Approval Study for the Treatment of Standard Surgical Risk Patients using TCAR

    SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease. The post-market study, called ROADSTER 3, will fulfill the U.S. Food and Drug Administration’s (FDA) condition of approval for the recent expansion of labeling for the ENROUTE® Transca

Advertisement
Advertisement